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0268-4705  2014 Wolters Kluwera,b a cAlban-Elouen Baruteau , Vincent Probst , and Hugues AbrielPurpose of review
Progressive cardiac conduction disorder (PCCD) is an inherited cardiac disease that may present as a
primary electrical disease or be associated with structural heart disease. In this brief review, we present
recent clinical, genetic, and molecular findings relating to PCCD.
Recent findings
Inherited PCCD in structurally normal hearts has been found to be linked to genetic variants in the ion
channel genes SCN5A, SCN1B, SCN10A, TRPM4, and KCNK17, as well as in genes coding for cardiac
connexin proteins. In addition, several SCN5A mutations lead to ‘cardiac sodium channelopathy overlap
syndrome’. Other genes coding for cardiac transcription factors, such as NKX2.5 and TBX5, are involved
in the development of the cardiac conduction system and in the morphogenesis of the heart. Mutations in
these two genes have been shown to cause cardiac conduction disorders associated with various
congenital heart defects.
Summary
PCCD is a hereditary syndrome, and genetic variants in multiple genes have been described to date.
Genetic screening and identification of the causal mutation are crucial for risk stratification and family
counselling.
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Major advances have recently been made in our
understanding of the development and pathophysi-
ology of progressive cardiac conduction disorders
(PCCDs) [1,2]. Descriptions of the various genetic
backgrounds behind the rare forms of familial
PCCDs have also been reported, highlighting
genotype–phenotype correlations and providing
crucial insights into the molecular determinants
of cardiac conduction [3]. This brief review aims
to describe recent major advances in our under-
standing of the clinical, genetic and molecular
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DOI:10.1097/HCO.0000000000000134THE CARDIAC CONDUCTION SYSTEM:
STRUCTURAL AND FUNCTIONAL
COMPONENTS
The sino-atrial node, the atrio-ventricular node and
the His-Purkinje system constitute the cardiac con-
duction system, which coordinates the initiation
and propagation of the electrical impulse in the
heart and the synchronous contraction of both
ventricles [3,4]. Recent studies have shown that
the cardiac conduction system has a unique
embryological origin that is distinct from that ofilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkthe working myocardium [5]. This system involves
more structures than originally thought, since it
englobes the atrio-ventricular rings, a third retro-
aortic node and the pulmonary and aortic sleeves
[1,6].
Recent findings have increased our understand-
ing of the role of cardiac ion channels underlying
the generation and propagation of the electrical
impulse through the cardiac conduction system.
The upstroke and repolarization of the sino-atrialthorized reproduction of this article is prohibited.
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CKEY POINTS
 Genetic factors play an important role in patients with
progressive cardiac conduction disorders.
 Recent studies have demonstrated that parents of
paediatric patients with cardiac conduction alterations
are also prone to conduction defects, demonstrating the
high heritability of this trait.
 Mutations in genes encoding cardiac ion channels, ion
channel-interacting proteins, cardiac transcription
factors and cytoskeletal elements can cause cardiac
conduction alterations.
 These recent findings illustrate the importance of
genetic screening and genetic counselling in patients
and families with cardiac conduction disorders.
Arrhythmiasnode are the result of depolarizing voltage-gated
calcium currents and repolarizing delayed rectifier
potassium currents, respectively [7,8]. Cardiac auto-
maticity is a result of diastolic depolarization, a
spontaneous slow depolarization towards the
threshold that generates a new action potential
[9]. Voltage-gated sodium channels and gap junc-
tions composed of connexin proteins are respon-
sible for the fast propagation of the action potential
through the atria, the His bundle, the Purkinje fibre
network and the ventricular myocytes [10].PROGRESSIVE CARDIAC CONDUCTION
DISORDER IS AN INHERITED DISORDER
Clinical and molecular studies have led to the
characterization of PCCD as an inherited disease.
First reports: familial pedigree of progressive
cardiac conduction disorder
In 1901, Morquio was the first to notice a familial
segregation of cardiac conduction disorders. A
genetic background had long been suggested, with
reports of familial clusters of isolated heart block
segregation in two or more generations [11]. In
1965, Gazes et al. [12] reported segregation of
Adams–Stokes seizures and second-degree heart
block in four generations of the same family,
suggesting a dominant inheritance. In the past dec-
ade, the field of molecular genetics has rapidly
expanded and provided crucial data on the genetic
basis of PCCD [13,14].
Genetic epidemiological approach to
progressive cardiac conduction disorder
On the basis of the hypothesis that, in an area where
the population is geographically stable, the off-
spring of an ancestor affected by a genetic diseaseopyright © Lippincott Williams & Wilkins. Unautho
34 www.co-cardiology.comremain in this same area during several generations
and a major difference in the disease repartition
could appear, a genetic epidemiological approach
was recently applied by Gourraud et al. [15] to show
familial aggregation for PCCD. Using French social
security numbers, the authors determined the city
of birth of more than 6600 patients implanted with
a pacemaker in the western part of France. Upon
mapping the frequency of pacemaker implantations
for PCCD, they observed a large heterogeneity in
disease frequency, from 0.21 to 2.28%, in specific
parishes. This study led to the identification of five
large families with PCCD, strongly supporting a
genetic background for PCCD.Congenital and childhood non-immune
isolated atrio-ventricular block is a genetic
disease
Congenital atrio-ventricular block is a rare disorder
with an estimated prevalence of 1 per 20000 live
births. Maternal autoimmune disease accounts for
90–99% of all cases diagnosed before 6 months of
age, where the trans-placental passage of maternal
anti-Ro/SSA and/or anti-La/SSB auto-antibodies
causes irreversible fibrosis of the fetal conduction
system, as well as the inhibition of cardiac L-type
calcium channels [16]. In the remaining cases in
which no obvious cause of atrio-ventricular block
can be identified, the heart block is considered to
be idiopathic.
In the first large-scale study, looking at the
heritability of paediatric idiopathic heart block in
a French nationwide cohort, Baruteau et al. [17,18]
observed a high degree of inheritance and a strong
genetic contribution in the pathogenesis of congen-
ital and childhood non-immune isolated atrio-ven-
tricular block. Nearly 70% of the patients with an
incomplete heart block progressed to a permanent
complete one, suggesting a postnatal degenerative
process of the conduction tissue [17,18]. The
authors hypothesized that this process may be
genetically determined. To test this hypothesis,
parents of the patients were invited to undergo a
screening 12-lead ECG. ECG screening in asympto-
matic parents of children affected by idiopathic
atrio-ventricular block revealed a high prevalence
of cardiac conduction alterations characterized by a
long P wave and prolonged PR and QRS intervals,
indicative of intra-atrial, atrio-ventricular and intra-
ventricular conduction abnormalities. Moreover,
well-characterized conduction disturbances (mainly
first-degree atrio-ventricular block, right bundle
branch block and left axis deviation) were more
frequent in parents of the patients of the cohort
than in matched healthy control individuals. Therized reproduction of this article is prohibited.
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Inherited progressive cardiac conduction disorders Baruteau et al.estimated heritability for isolated conduction
disturbances was 91% and two SCN5A mutations
were identified in the affected children, confirming
that congenital and childhood non-immune iso-
lated atrio-ventricular block is a highly heritable
trait [18,19].CLINICAL/MOLECULAR DESCRIPTION OF
INHERITED PROGRESSIVE CARDIAC
CONDUCTION DISORDER IN
STRUCTURALLY NORMAL HEARTS
Progressive cardiac conduction disorder may
present as a primary electrical disease.SCN5A
Cardiac sodium channel dysfunction caused by
mutations in the SCN5A gene leads to a broad
spectrum of hereditary arrhythmias with variable
phenotypic expression [20]. The phenotypic spec-
trum ranges from lethal arrhythmias to asympto-
matic carriers, and includes Brugada syndrome,
cardiac conduction disease and atrio-ventricular
block, congenital sick sinus syndrome, atrial stand-
still, familial atrial fibrillation, dilated cardiomyop-
athy, congenital long-QT syndrome type 3 (LQT3)
and sudden infant death syndrome [21]. The gene
SCN5A codes for the main cardiac voltage-gated
sodium channel Nav1.5 [20], which is expressed
in the conduction system and in the regions sur-
rounding the sino-atrial and the atrio-ventricular
nodes [7]. Thus far, at least 16 distinct mutations
in SCN5A have been found to cause conduction
alterations and block in patients and their families
[22]. The vast majority of these mutations, when
functionally characterized [23], reduced the sodium
current, thereby leading to a loss of function con-
sistent with the slowed cardiac conduction observed
in patients.SCN5A overlap syndrome
SCN5A mutation carriers tend to exhibit overlap-
ping clinical manifestations of the distinct SCN5A-
related syndromes, which is defined as ‘SCN5A
overlap syndrome’ [24]. In many cases, cardiac
conduction is altered in these patients. Recently,
Kanter et al. [25] reported ventricular arrhythmias
and intra-ventricular conduction delays in young
children due to loss-of-function sodium and/or
calcium channelopathies. Other recently reported
SCN5A mutation-related overlap syndromes
included LQT3 and dilated cardiomyopathy [26],
LQT3 and early-onset lone atrial fibrillation [27],
LQT3 and Brugada syndrome [28], and BrugadaCopyright © Lippincott Williams & Wilkins. Unau
0268-4705  2014 Wolters Kluwer Health | Lippincott Williams & Wilksyndrome, conduction disease and atrial flutter
[29
&
].SCN1B
The cardiac sodium channel protein Nav1.5, which
constitutes the pore-forming subunit, has been
shown to be part of distinct multi-protein com-
plexes in different membrane compartments of
the cardiac cells [30]. Among the proteins interact-
ing directly with Nav1.5, at least four beta-subunits
were shown to modulate the expression and func-
tion of the sodium channel [31].Watanabe et al. [14]
recently found three pathogenic mutations in the
gene SCN1B, which codes for the beta1 subunit of
the voltage-gated sodium channel, in families
with conduction alterations and, in certain cases,
Brugada syndrome. All three mutations were shown
to decrease the Nav1.5-mediated current in cellular
expression system compared with controls.SCN10A
In several large, genome-wide association studies,
loci within the SCN10A gene, coding for the voltage-
gated sodium channel Nav1.8, were found to be
associated with atrio-ventricular conduction [32]
and Brugada syndrome [33
&&
]. Although the expres-
sion of Nav1.8 in cardiac cells is still under debate
[34,35], a recent study [36] provided evidence that a
cardiac enhancer in SCN10A interacts with and
regulates the promoter of SCN5A, thus providing
an explanation for how SCN10A genetic variants
may affect conduction. The details of these complex
regulatory mechanisms are still not well under-
stood, and may also be complicated by the obser-
vation that many variants of SCN10A were found to
be present in patients with Brugada syndrome [37
&&
].Connexins
Cardiac gap junctions are composed of proteins
called connexins (Cxs), which form low-resistance
channels that allow electrical coupling and inter-
cellular electrical communication [10]. Four con-
nexin isoforms are expressed in the human heart
with regional distribution: Cx40, which forms large-
conductance gap junction channels; Cx43, which
forms medium-conductance gap junction channels;
Cx45, which forms small-conductance gap junction
channels; and Cx31.9, which forms ultra-small-
conductance gap junction channels [38]. Altera-
tions in the expression of cardiac connexins may
cause abnormal activation to spread through the
myocardium and lead to conduction disorders. In
a recent study, Makita et al. [39] first demonstratedthorized reproduction of this article is prohibited.
ins www.co-cardiology.com 35
CArrhythmiasa causal relationship between nucleotide substi-
tutions in gene coding for connexin-40 protein
and progressive familial heart block. From a screen-
ing of 156 probands with progressive familial heart
block, they identified a mutation in the gene encod-
ing Cx40 (Q58L) in one family. Heterologous
expression of Cx40-Q58L in connexin-deficient
cells resulted in a marked reduction in junctional
conductance and the diffuse localization of Cx40
proteins in the vicinity of the plasma membrane,
without the formation of gap junctions. This study,
which was the first to demonstrate a germ-line
mutation in a connexin gene associated with inher-
ited conduction disorders, emphasizes the import-
ance of Cx40 in the normal propagation of the
electrical impulse in the specialized cardiac conduc-
tion system.
TRPM4
Recently, the transient receptor potential (TRP)
channel TRPM4 has been implicated in different
cardiac disorders [40]. Kruse et al. [41] described
the first TRPM4 mutation, p. E7K, in an Afrikaner
family with a familial conduction disorder. The
affected individuals were heterozygous carriers of
the mutation, which was transmitted in a dominant
fashion. In cellular expression systems, mutant
TRPM4 channels produce a larger current than their
wild-type counterparts, possibly due to an insensi-
tivity to deSUMOylation, thus impairing endocyto-
sis and stabilizing the mutant channels at the cell
surface [41]. More recently, three more mutations
in TRPM4 were reported in French and Lebanese
families with PCCD [42]. Functional experiments
expressing these three mutant variants of TRPM4
suggested a similar gain-of-function phenomenon
related to altered deSUMOylation. In another recent
study [43], an additional six TRPM4 mutations in
patients with right bundle branch block and atrio-
ventricular block were identified, but electrophysio-
logical or biochemical studies have yet to be carried
out in order to elucidate the potential mechanisms
involved. Altogether, these recent studies strongly
suggest that the cardiac channel TRPM4 plays a key
role in the pathogenesis of genetically determined
conductiondisorders. Itmaybe that gain-of-function
mutant TRPM4 channels lead to cell membrane
depolarization in the conduction system, thus reduc-
ing the number of available sodium channels and
resulting in the observed conduction abnormalities.KCNK17
In a recent study [44
&
] reporting on a PCCD patient
with idiopathic ventricular fibrillation, whole
exome sequencing identified a missense mutation,opyright © Lippincott Williams & Wilkins. Unautho
36 www.co-cardiology.comG88R, in the gene KCNK17, which codes for the
potassium channel TASK-4. This mutation led to a
gain of function of the TASK-4-mediated current
and may, similarly to the gain-of-function mechan-
isms proposed for TRPM4 [40], reduce the availabil-
ity of the sodium current by depolarizing the
membrane of conduction system cells. Importantly,
this study also demonstrated the expression of the
TASK-4 channel in human Purkinje cells [44
&
].CLINICAL AND MOLECULAR DESCRIPTION
OF INHERITED PROGRESSIVE CARDIAC
CONDUCTION DISORDER ASSOCIATED
WITH CONGENITAL HEART DISEASES
Several genes encoding cardiac transcription factors
are essential for the development of the conduction
system as well as in cardiac septation and morpho-
genesis. Recent genetic findings suggest that
approximately 10% of sporadic congenital heart
diseases may have de-novo mutations that signifi-
cantly contribute to the disease process [45,46
&&
,47].
A molecular pathway including TBX5, NKX2.5 and
Id2 genes coordinates the specification of ventricu-
lar myocytes into the ventricular conduction system
lineage [48]. Moreover, several transcription factors
modify gene expression of ion channel proteins that
contribute to the electrophysiological properties of
the conduction system and govern the contraction
of the surrounding myocardium [49]. Mutations in
genes encoding for core transcription factors critical
for cardiac chamber formation, endocardial cushion
remodelling and conduction system development,
like NKX2.5 and Tbx5, may lead to progressive
cardiac conduction disorders associated with con-
genital heart diseases [50].NKX2.5
The first study identifying mutations in the gene
coding for the cardiac-specific homeobox trans-
cription factor NKX2.5 was in four families with
secundum atrial septal defects (ASDs) and atrio-
ventricular conduction disorders [51]. Since then,
numerous mutations in this transcription factor
have been reported with various congenital heart
defect phenotypes, such as secundum ASD, tetral-
ogy of Fallot, truncus arteriosus, double-outlet right
ventricle, L-transposition of great arteries, inter-
rupted aortic arch and hypoplastic left heart syn-
drome, with or without conduction disorders [52].
More recently, Wenckebach periodicity, ventricular
non-compaction and sudden death have been
added to the spectrum of clinical manifestations
associated with NKX2.5 mutations [53,54], and
experimental studies have confirmed that NKX2.5rized reproduction of this article is prohibited.
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conduction myocardium in coordination with
Notch pathway [55
&&
].
Tbx5
In 1997, Basson et al. [56] screened two families with
Holt–Oram syndrome and identified mutations in
the gene encoding the T-box transcription factor
Tbx5. Holt–Oram syndrome is characterized by
radial ray upper limb abnormalities and cardiac
septation defects with an autosomal dominant
transmission pattern. The septal defects consist of
secundum ASD, muscular ventricular septal defects
or atrioventricular septal defects and may also be
associated with aortic coarctation [57]. Affected
patients also present various degrees of conduction
disorders, such as sinus bradycardia and atrio-ven-
tricular block, even in the absence of overt structural
heart disease [58]. Another member of the T-box
family transcription factor, TBX3, is found in close
proximity to TBX5 on chromosome 12q24.
Mutations in TBX3 cause ulnar-mammary syn-
drome, and an exceptional case of contiguous
deletions of both TBX5 and TBX3 has been recently
reported in a patient with features of both Holt–
Oram syndrome and ulnar-mammary syndrome,
consisting of bilateral symmetric limb malfor-
mations, congenital heart defects and rapidly pro-
gressive cardiac conduction disease [59
&
].DIAGNOSTIC AND THERAPEUTIC
MANAGEMENT OF PATIENTS WITH
INHERITED PROGRESSIVE CARDIAC
CONDUCTION DISORDER
Inherited progressive cardiac conduction disease is
mainly diagnosed in the presence of unexplained
progressive conduction abnormalities in individuals
younger than 50 years with structurally normal
hearts, in the absence of skeletal myopathies, especi-
ally if there is a family history of PCCD. The diag-
nosis of PCCD in an index patient is based on
clinical data (history, family history, 12-lead
ECG), and a two-dimensional (2D) echocardiogra-
phy or cardiac MRI when needed to exclude an
underlying congenital heart disease and/or cardio-
myopathy. Early-onset PCCD in structurally normal
heart should prompt consideration of PCCD genetic
testing, particularly if there is a family history of
PCCD, pacemaker implant or sudden death [60].
Unfortunately, thus far, there is no genotype-based
risk stratification that is available. Clinicians should
keep a low threshold for investigating symptoms
or ECG findings to determine the need for
electrophysiological studies or pacemaker implan-
tation. Management of PCCD patients includesCopyright © Lippincott Williams & Wilkins. Unau
0268-4705  2014 Wolters Kluwer Health | Lippincott Williams & Wilkrestriction of medications with conduction-slowing
properties, as well as active treatment of fever in
SCN5A mutation carriers. The Heart Rhythm
Society/European Heart Rhythm Association/Asia-
Pacific Heart Rhythm Society expert consensus
statement considers that permanent pacemaker
implantation is recommended in PCCD patients
with either intermittent or permanent third-degree
or high-grade atrio-ventricular block, or sympto-
matic Mobitz I or II second-degree atrio-ventricular
block (class I recommendation). Pacemaker implan-
tation can be useful in PCCD patients with bifascic-
ular block with or without first-degree atrio-
ventricular block (class IIa recommendation) [61].
Targeted genetic screening of first-degree relatives of
a mutation-positive PCCD patient is also part of the
management, to allow prospective follow-up of
asymptomatic mutation carriers.CONCLUSION
A large number of genes have been linked to cardiac
conduction disorders. It is now clear that cardiac
conduction defects are not only associated with
aging, but that many complex pathophysiological
processes may lead to the occurrence of atrio-ven-
tricular and intra-ventricular block. Many genes and
gene networks are involved in the electrophysiologi-
cal activity of the heart, and it is likely that only a
small fraction of these genetic defects have been
currently identified. In the future, it could be
possible to determine most of the causative genetic
alterations and in turn determine the actual pro-
portion of conduction disorders due to genetic
defects. Once this first step is achieved, genetic
analysis would be part of the routine clinical assess-
ment of patients affected by PCCD. Since the
appearance of these conduction alterations is a slow
process over time, genetic tests could help to better
determine the risk of progression of a cardiac con-
duction defect and hence determine the best timing
for pacemaker implantation. In the longer term, it
may be possible, through early identification of
patients at risk of developing cardiac conduction
defects, notably by familial screening, to develop
preventive strategies, using drugs able to slow the
development of these potentially fatal disorders.
Acknowledgements
The authors thank Biotelligences LLC (Lausanne,
Switzerland) for their suggestions on the text of this
manuscript.Financial support and sponsorship
None.thorized reproduction of this article is prohibited.
ins www.co-cardiology.com 37
CArrhythmiasConflicts of interest
There are no conflicts of interest.REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest1. Dobrzynski H, Anderson RH, Atkinson A, et al. Structure, function and clinical
relevance of the cardiac conduction system, including the atrioventricular ring
and outflow tract tissues. Pharmacol Ther 2013; 139:260–288.
2. Gilbert-Barness E. Conduction defects/cardiomyopathies. Adv Pediatr 2014;
61:127–148.
3. Munshi NV. Gene regulatory networks in cardiac conduction system devel-
opment. Circ Res 2012; 110:1525–1537.
4. Anderson RH, Yanni J, Boyett MR, et al. The anatomy of the cardiac con-
duction system. Clin Anat 2009; 22:99–113.
5. Gourdie RG, Harris BS, Bond J, et al.Development of the cardiac pacemaking
and conduction system. Birth Defects Res C Embryo Today 2003; 69:46–
57.
6. Yanni J, Boyett MR, Anderson RH, et al. The extent of the specialized
atrioventricular ring tissues. Heart Rhythm 2009; 6:672–680.
7. Monfredi O, Dobrzynski H, Mondal T, et al. The anatomy and physiology of the
sinoatrial node: a contemporary review. Pacing Clin Electrophysiol 2010;
33:1392–1406.
8. Nikolaidou T, Aslanidi OV, Zhang H, et al. Structure-function relationship
in the sinus and atrioventricular nodes. Pediatr Cardiol 2012; 33:890–
899.
9. Barbuti A, Baruscotti M, DiFrancesco D. The pacemaker current: from basics
to the clinics. J Cardiovasc Electrophysiol 2007; 18:342–347.
10. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and
associated arrhythmias. Physiol Rev 2004; 84:431–488.
11. Lynch HT, Mohiuddin S, Sketch MH, et al. Hereditary progressive atrioven-
tricular conduction defect. A new syndrome? JAMA 1973; 225:1465–1470.
12. Gazes PC, Culler RM, Taber E, et al. Congenital familial cardiac conduction
defects. Circulation 1965; 32:32–34.
13. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate
with mutations in SCN5A. Nat Genet 1999; 23:20–21.
14. Watanabe H, Koopmann TT, Le SS, et al. Sodium channel beta1 subunit
mutations associated with Brugada syndrome and cardiac conduction dis-
ease in humans. J Clin Invest 2008; 118:2260–2268.
15. Gourraud JB, Kyndt F, Fouchard S, et al. Identification of a strong genetic
background for progressive cardiac conduction defect by epidemiological
approach. Heart 2012; 98:1305–1310.
16. Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of
congenital heart block. Exp Cell Res 2014; 325:2–9.
17. Baruteau AE, Fouchard S, Behaghel A, et al. Characteristics and long-term
outcome of nonimmune isolated atrioventricular block diagnosed in utero or
early childhood: a multicentre study. Eur Heart J 2012; 33:622–629.
18. Baruteau AE, Behaghel A, Fouchard S, et al. Parental electrocardiographic
screening identifies a high degree of inheritance for congenital and childhood
non-immune isolated atrio-ventricular block. Circulation 2012; 126:1469–
1477.
19. Cannon BC, Ackerman MJ. Surprise, surprise: idiopathic, isolated complete
atrioventricular block may be heritable. Circulation 2012; 126:1434–
1435.
20. Abriel H. Cardiac sodium channel Nav1.5 and interacting proteins: physiology
and pathophysiology. J Mol Cell Cardiol 2010; 48:2–11.
21. Remme CA. Cardiac sodium channelopathy associated with SCN5A muta-
tions: electrophysiological, molecular and genetic aspects. J Physiol 2013;
591:4099–4116.
22. Kovach JR, Benson DW. Conduction disorders and Nav1.5. Cardiol Clin
2014; 6:723–731.
23. Zimmer T, Surber R. SCN5A channelopathies: an update on mutations and
mechanisms. Prog Biophys Mol Biol 2008; 98:120–136.
24. Remme CA, Wilde AAM, Bezzina CR. Cardiac sodium channel overlap
syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med
2008; 18:78–87.
25. Kanter RJ, Pfeiffer R, Hu D, et al. Brugada-like syndrome in infancy presenting
with rapid ventricular tachycardia and intraventricular conduction delay.
Circulation 2012; 125:14–22.
26. Kwon HW, Lee SY, Kwon BS, et al. Long QT syndrome and dilated
cardiomyopathy with SCN5A p.R1193Q polymorphism: cardioverter-defibril-
lator implantation at 27 months. Pacing Clin Electrophysiol 2012; 35:e243–
e246.
27. Olesen MS, Yuan L, Liang B, et al. High prevalence of long QT syndrome-
associated SCN5A variants in patients with early-onset lone atrial fibrillation.
Circ Cardiovasc Genet 2012; 5:450–459.opyright © Lippincott Williams & Wilkins. Unautho
38 www.co-cardiology.com28. Nakaya H. SCN5A mutations associated with overlap phenotype of long
QT syndrome type 3 and Brugada syndrome. Circ J 2014; 78:1061–
1062.
29.
&
Hothi SS, Ara F, Timperley JP. Y1449C SCN5A mutation associated with
overlap disorder comprising conduction disease, Brugada syndrome, and
atrial flutter. J Cardiovasc Electrophysiol 2014. [Epub ahead of print]
An interesting study reporting familial segregation of a SCN5A mutation in a single
family with a spectrum of cardiac phenotypes including conduction disease,
Brugada syndrome and atrial arrhythmias.
30. Shy D, Gillet L, Abriel H. Cardiac sodium channel Nav1.5 distribution in
myocytes via interacting proteins: the multiple pool model. Biochim Biophys
Acta 2013; 1833:886–894.
31. Brackenbury WJ, Isom LL. Naþ channel b subunits: overachievers of the ion
channel family. Front Pharmacol 2011; 2:53.
32. Pfeufer A, van NC, Marciante KD, et al.Genome-wide association study of PR
interval. Nat Genet 2010; 42:153–159.
33.
&&
Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A
and HEY2 are associated with Brugada syndrome, a rare disease with high
risk of sudden cardiac death. Nat Genet 2013; 45:1044–1049.
A genome-wide association study of 312 individuals with Brugada syndrome and
1115 controls demonstrating that common genetic variants can have a strong
impact on the predisposition to rare diseases.
34. Verkerk AO, Remme CA, Schumacher CA, et al. Functional Nav1.8 channels
in intracardiac neurons: the link between SCN10A and cardiac electrophy-
siology. Circ Res 2012; 111:333–343.
35. Yang T, Atack TC, Stroud DM, et al. Blocking SCN10A channels in heart
reduces late sodium current and is antiarrhythmic. Circ Res 2012; 111:322–
332.
36. van den Boogaard M, Smemo S, Burnicka-Turek O, et al. A common genetic
variant within SCN10A modulates cardiac SCN5A expression. J Clin Invest
2014; 124:1844–1852.
37.
&&
Hu D, Barajas-Martinez H, Pfeiffer R, et al. Mutations in SCN10A are
responsible for a large fraction of cases of Brugada syndrome. J Am Coll
Cardiol 2014; 64:66–79.
From a cohort of 150 probands and family members and more than 200 healthy
controls, this study identifies SCN10A as a major susceptibility gene for BrS, thus
greatly enhancing our ability to genotype and risk stratify probands and family
members.
38. Temple IP, Inada S, Dobrzynski H, et al. Connexins and the atrioventricular
node. Heart Rhythm 2013; 10:297–304.
39. Makita N, Seki A, Sumitomo N, et al. A connexin40 mutation associated with a
malignant variant of progressive familial heart block type I. Circ Arrhythm
Electrophysiol 2012; 5:163–172.
40. Abriel H, Syam N, Sottas V, et al. TRPM4 channels in the cardiovascular
system: physiology, pathophysiology, and pharmacology. Biochem Pharma-
col 2012; 84:873–881.
41. Kruse M, Schulze-Bahr E, Corfield V, et al. Impaired endocytosis of the ion
channel TRPM4 is associated with human progressive familial heart block
type I. J Clin Invest 2009; 119:2737–2744.
42. Liu H, El ZL, Kruse M, et al. Gain-of-function mutations in TRPM4 cause
autosomal dominant isolated cardiac conduction disease. Circ Cardiovasc
Genet 2010; 3:374–385.
43. Stallmeyer B, Zumhagen S, Denjoy I, et al. Mutational spectrum in the Ca(2þ)
activated cation channel gene TRPM4 in patients with cardiac conductance
disturbances. Hum Mutat 2011; 33:109–117.
44.
&
Friedrich C, Rinne S, Zumhagen S, et al. Gain-of-function mutation in TASK-4
channels and severe cardiac conduction disorder. EMBO Mol Med 2014;
6:937–951.
Whole-exome sequencing identified mutation in the KCNK17 gene encoding the
K2P potassium channel TASK-4 to be associated with cardiac conduction dis-
order.
45. Bruneau BG. The developmental genetics of congenital heart disease. Nature
2008; 451:943–948.
46.
&&
Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying
genes in congenital heart disease. Nature 2013; 498:220–223.
This important study compares the incidence of de-novo mutations in 362 severe
congenital heart disease cases and 264 controls by analysing exome sequencing
of parent-offspring trios. Authors find a marked excess of de-novo mutations in
histone-modifying genes in congenital heart disease.
47. Bruneau BG, Srivastava D. Congenital heart disease: entering a new era of
human genetics. Circ Res 2014; 114:598–599.
48. Moskowitz IP, Kim JB, Moore ML, et al. A molecular pathway including Id2,
Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell
2007; 129:1365–1376.
49. Sizarov A, Devalla HD, Anderson RH, et al. Molecular analysis of patterning of
conduction tissues in the developing human heart. Circ Arrhythm Electro-
physiol 2011; 4:532–542.
50. McCulley DJ, Black BL. Transcription factor pathways and congenital heart
disease. Curr Top Dev Biol 2012; 100:253–277.
51. Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused
by mutations in the transcription factor NKX2-5. Science 1998; 281:108–
111.
52. McElhinney DB, Geiger E, Blinder J, et al. NKX2.5 mutations in patients with
congenital heart disease. J Am Coll Cardiol 2003; 42:1650–1655.rized reproduction of this article is prohibited.
Volume 30  Number 1  January 2015
Inherited progressive cardiac conduction disorders Baruteau et al.53. Ouyang P, Saarel E, Bai Y, et al. A de novo mutation in NKX2.5 associated
with atrial septal defects, ventricular noncompaction, syncope and sudden
death. Clin Chim Acta 2011; 412:170–175.
54. Guntheroth W, Chun L, Patton KK, et al. Wenckebach periodicity at rest that
normalizes with tachycardia in a family with a NKX2.5 mutation. Am J Cardiol
2012; 110:1646–1650.
55.
&&
Nakashima Y, Yanez DA, Touma M, et al. Nkx2-5 suppresses the proliferation
of atrial myocytes and conduction system. Circ Res 2014; 114:1103–1113.
This study suggests that Nkx2-5 regulates the proliferation of atrial working and
conduction myocardium in coordination with Notch pathway.
56. Basson CT, Bachinsky DR, Lin RC, et al. Mutations in human TBX5 [cor-
rected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat
Genet 1997; 15:30–35.
57. Baban A, Pitto L, Pulignani S, et al. Holt-Oram syndrome with intermediate
atrioventricular canal defect, and aortic coarctation: functional characteriza-
tion of a de novo TBX5 mutation. Am J Med Genet A 2014; 164A:1419–
1424.Copyright © Lippincott Williams & Wilkins. Unau
0268-4705  2014 Wolters Kluwer Health | Lippincott Williams & Wilk58. McDermott DA, Fong JC, Basson CT. Holt-Oram syndrome. In Pagon RA, Heal
AMA, editors. GeneReviews [Internet]. Seattle, WA: University ofWashington;
1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1111/.
59.
&
Bogarapu S, Bleyl SB, Calhoun A, et al. Phenotype of a patient with
contiguous deletion of TBX5 and TBX3: expanding the disease spectrum.
Am J Med Genet A 2014; 164A:1304–1309.
Authors report on a patient with features of both Holt–Oram syndrome and ulnar-
mammary syndrome consisting of bilateral symmetric limb malformations, con-
genital cardiac defects, and rapidly progressive cardiac conduction disease.
60. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus
statement on the state of genetic testing for the channelopathies and
cardiomyopathies. Europace 2011; 13:1077–1109.
61. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus
statement on the diagnosis and management of patients with inherited
primary arrhythmia syndromes: document endorsed by HRS, EHRA, and
APHRS in May 2013 and by ACCF AHA, PACES, and AEPC in June 2013.
Heart Rhythm 2013; 10:1932–1963.thorized reproduction of this article is prohibited.
ins www.co-cardiology.com 39
